























































Substantial Heterogeneity in Progress Toward Reaching the
90-90-90 HIV Target in the WHO European Region
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the ECDC Dublin Declaration Monitoring Network
Background: Achieving the UNAIDS 90-90-90 target by 2020 is
expected to end the HIV epidemic by 2030. We report on progress in
the WHO European Region in meeting this target.
Methods: The European Centre for Disease Prevention and Control
(ECDC) sent questionnaires to 55 countries in 2016. We report
estimates for 4 stages of the continuum of HIV care (living with
HIV, diagnosed, treated, and virally suppressed), corresponding to
the Joint United Nations Programme on HIV and AIDS (UNAIDS)
target and explore differences by subregion and challenges with
reporting data.
Findings: Forty-four countries provided data for $1 stage, and
29 for all 4 stages. Estimated HIV prevalence was 0.19% (range
0.02%–0.84%, n = 37 countries providing stage 1 data). The
proportion diagnosed of people living with HIV ranged from 38%
to 98% (n = 37 reporting number of people living with HIV and
diagnosed). The proportion on ART of those diagnosed ranged
from 27% to 96% (n = 40 reporting numbers diagnosed and
treated), and viral suppression rates ranged from 32% to 97% (n =
31 providing numbers treated and virally suppressed). The overall
continuum of care estimate for 29 countries with complete data
was 81-84-88, which differed by subregion: 84-88-90, 84-69-62,
and 57-45-57 for the western, central, and eastern subregions,
respectively. Challenges in reporting data included absence of
a single data source for all stages, shortage of expertise, and lack
of ﬁnancial and human resources.
Conclusions: There is an urgent need to strengthen HIV testing
programs throughout Europe, particularly in the eastern subregion,
and to remove constraints hampering access to testing and care.
Recent changes to treatment guidelines should help reduce the
numbers diagnosed not treated.
Key Words: continuum of HIV care, cascade of care, Europe,
prevalence, HIV diagnoses
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INTRODUCTION
Of the estimated 36.7 million people living with HIV
(PLHIV) globally in 2015, 2.5 million (6.8%) were in the
World Health Organization (WHO) European Region,1
including 5 central Asian countries.2 Of the 2 million new
infections globally in 2015, 170,000 (8.5%) are estimated to
have taken place in that region.3 Although there is evidence of
a stabilizing or decrease in numbers of newly infected
elsewhere, rates of new adult HIV infections have increased
dramatically in Eastern Europe and Central Asia.4
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The region’s 153,400 people newly diagnosed with
HIV in 2015 corresponded to a rate of 17.6 per 100,000
population, a 7% increase over the previous year.5 The vast
majority (79%) were in the eastern subregion comprising
the 15 former Soviet Union countries, including Russia.
Rates of new HIV diagnoses have consistently been highest
in the eastern and lowest in the central subregions.
Epidemic patterns differ between the 3 subregions, with
the highest proportions of HIV diagnoses documented
among men having sex with men in the western and central
subregions, and among people who inject drugs or sex
between men and women in the eastern subregion.5 Male to
female ratios among PLHIV are, as a consequence, much
higher in the western and central vs. eastern subregions.5
Since 2010, the European Centre for Disease Pre-
vention and Control (ECDC) has supported countries in
monitoring progress on their commitment to implementing
the Dublin Declaration on Partnership to Fight HIV/AIDS in
Europe and Central Asia.6 To monitor progress, a request is
made to the relevant authority in each country to provide
information through a tailored questionnaire on a number of
key HIV-related issues. The questionnaire is sent out every 2
years and has, since 2014, included speciﬁc questions aimed
at quantifying the stages of the continuum of HIV care in each
country.7
The HIV continuum of care, or cascade of care, has
emerged as a useful tool for monitoring the care pathway of
PLHIV from diagnosis, through to engagement with and
retention in care, initiating and maintaining adherence to
antiretroviral therapy (ART), and achieving viral suppression.
The concept of deﬁning transition through health care stages
was ﬁrst proposed in 1972 in relation to hypertension8 and
gained traction when it was applied to the HIV population in
the United States.9
In 2014, the Joint United Nations Programme on HIV
and AIDS (UNAIDS) launched the 90-90-90 target10 for
countries to ensure that, by 2020, at least 90% of PLHIV are
diagnosed, of whom 90% are on ART and of whom 90% are
virally suppressed. The ambitious target corresponds to 4
stages of the continuum of HIV care and is supported by
modeling work indicating that viral suppression among all
PLHIV must reach very high levels to reduce HIV incidence
signiﬁcantly.11
Using data reported through the Dublin Declaration
questionnaire 2016,7 our aim here is to report the best
available estimates of the 90-90-90 target for the
WHO European Region and make a number of recom-
mendations aimed at supporting countries achieve the
UNAIDS target.
METHODS
The 2016 Dublin Declaration questionnaire7 was
sent in December 2015 to all 53 member states of the
WHO European Region and to Liechtenstein and Kosovo
(This designation is without prejudice to positions on
status and is in line with UNSC 1244 and the ICJ Opinion
on the Kosovo Declaration of Independence), which are
not WHO member states (Appendix 2). As part of the
process, the ECDC provided guidance on deﬁnitions for
the stages of the care continuum (Table 1), requested
information on data sources, the year to which data
referred, and followed up on data submitted, resulting in
further data submission and clariﬁcation by
reporting countries.
We report on the data submitted by countries on the
HIV continuum of care estimates, focusing on differences
between the subregions. For each country, we present the
absolute number and/or proportion at each stage (1, the
total number of PLHIV; 2, the number/proportion diag-
nosed; 3, the number/proportion on ART; and 4, the
number/proportion virally suppressed), using the previous
stage as the denominator. The overall proportion sup-
pressed was also estimated using the denominator of all
PLHIV. We estimate HIV prevalence for each country that
reported data for stage 1, using Eurostat population data for
2015 (all ages) as denominator.12 For the 29 countries that
provided complete data for all 4 stages, we then combined
estimates to provide a regional estimate that aligns with the
90-90-90 target.
From the estimated number of individuals conceptually
“lost,”13 or omitted by deﬁnition, from each stage of the
continuum, ie, those with unsuppressed viremia, we derive
the proportion each stage contributes to the total number of
people living with unsuppressed viremia by taking the
difference in absolute numbers between each stage and
dividing by the overall number unsuppressed.
We report on progress since 2014 in achieving 90-90-
90 and explore possible reasons for any improvements in
estimates. Although deﬁnitions were provided to countries for
the 4 stages in 2016 (Table 1), no deﬁnitions were provided in
2014.7,14 Comparisons should, therefore, be made
with caution.
We also explore reasons for the lack of continuum data
in countries and examine the main challenges in collecting
and reporting data. Rates of new HIV diagnoses by country,
obtained from published data,5 are also assessed by subregion
and by whether continuum data were reported or not in the
2016 survey, to help assess the likely direction of any
potential bias in our estimates.
TABLE 1. Definitions Used to Monitor the Continuum of HIV
Care in the Dublin Declaration Monitoring Questionnaire
2016
Stage 1: total estimated number of PLHIV in the country. The total estimated
number should be based on an empirical modeling approach, using the
ECDC HIV modeling tool,19 spectrum29 or any other empirical estimate.
The estimate should include diagnosed and undiagnosed people.
Stage 2: number/percentage of above estimated number of PLHIV in the
country ever diagnosed. The number should include all new HIV or AIDS
diagnoses. It should also include those people who are in care and those
who have not been linked to care.
Stage 3: number/percentage of above estimated number of PLHIV in the
country ever diagnosed who are currently on antiretroviral treatment. The
number should include all people currently on antiretroviral treatment,
regardless of treatment regimen or treatment interruptions/discontinuation.
Stage 4: number/percentage of above estimated number of PLHIV in the
country ever diagnosed and on antiretroviral treatment who had viral load
#200 copies/mL at last visit (virally suppressed)
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Western Austria† 2013 6527 5745 88% 4891 85% 3718 76% 57%
Western Belgium 2014 17,744 14,977 84% 12,540 84% 11,965 95% 67%
Western Denmark 2014 5500 5000 91% 4700 94% 4400 94% 80%
Western France 2013 153,100 128,300 84% 114,825 89% 104,108 91% 68%
Western Germany 2015 84,700 72,000 85% 60,700 84% 56,400 93% 67%
Western Greece 2013 14,200 11,096 78% 7488 67% 5499 73% 39%
Western Ireland 2015 6180 5253 85% 4728 90%
Western Israel 2015 9720 7171 74% 4928 69%
Western Italy 2012 127,324 112,222 88% 98,755 88% 85,917 87% 67%
Western Luxembourg 2015 1065 927 87% 696 75% 635 91% 60%
Western Malta 2016 394 295 75% 284 96% 244 86% 62%
Western Netherlands 2015 22,900 20,083 88% 17,721 88% 16,456 93% 72%
Western Norway 2015 3750
Western Portugal 2014 59,365 41,793 70% 28,020 67% 21,965 78% 37%
Western Spain 2013–
2014
141,000 115,620 82% 106,370 92% 93,606 88% 66%
Western Sweden 2015 7718 6946 90% 6605 95% 6299 95% 82%
Western Switzerland 2015 16,500 13,500 82% 12,300 91% 11,900 97% 72%
Western United
Kingdom
2015 101,200 87,700 87% 83,900 96% 78,900 94% 78%
Central Albania 2015 1400 698 50% 456 65% 144 32% 10%
Central Bulgaria 2015 3543 2267 64% 824 36% 715 87% 20%
Central Croatia 2015 1680 1097 65% 953 87% 834 88% 50%
Central Cyprus 2015 983
Central Czech
Republic
2015 2281 1616 71% 1367 85%
Central Hungary 2015 3067 2667 87% 1423 53% 1324 93% 43%
Central Kosovo 2015 46 14 30%
Central Montenegro 2015 194 147 76% 99 67% 68 69% 35%
Central Poland 2015–
2016
35,000 19,915 57% 12,465 63%
Central Romania 2014–
2015
14,000 13,766 98% 10,551 77% 5386 51% 38%
Central Serbia 2014 3100 1956 63% 1300 66% 1235 95% 40%
Central Slovakia 2015 850 674 79%
Central Slovenia 2015–
2016
541 492 91% 406 83%
Eastern Armenia 2015 3600 1714 48% 941 55% 638 68% 18%
Eastern Azerbaijan 2015 8798 4704 53% 2960 63% 1542 52% 18%
Eastern Estonia 2015–
2016
11,000 9263 84% 3715 40%
Eastern Georgia 2015 9600 4339 45% 3044 70% 2369 78% 25%
Eastern Kazakhstan 2015 23,000 17,726 77% 6285 35% 3416 54% 15%
Eastern Kyrgyzstan 2015 8500 4767 56% 2109 44% 1030 49% 12%
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RESULTS
Data Availability
The response rate to the Dublin Declaration question-
naire was high (48 of 55 countries, 87%). No continuum data
were reported by 11 countries; 7 did not respond to the
questionnaire, and 4 returned the questionnaire but provided
no continuum data for any stage (Table 2 and Fig. 1).
Countries in the eastern subregion that did not report
any continuum data had appreciably higher rates of new
HIV diagnoses than eastern countries reporting continuum
data, and the highest rates of new HIV diagnoses overall

































Eastern Latvia 2015 5091 1388 27%
Eastern Lithuania 2015 3100 2173 70% 646 30%
Eastern Moldova 2015 17,985 10,213 57% 3850 38% 2667 69% 15%
Eastern Tajikistan 2015 16,000 6117 38% 3135 51% 995 32% 6%
Eastern Ukraine 2015 223,000 126,604 57% 60,753 48%
Eastern Uzbekistan 2015 36,553 19,026 52% 13,186 69%
Liechtenstein and Kosovo are not WHO European Region member states. Year of estimate not provided for Kosovo. The Dublin Declaration questionnaires were not returned from
7 countries (Belarus, Former Yugoslav Republic of Macedonia, Liechtenstein, Monaco, Russian Federation, San Marino, and Turkmenistan), and the questionnaire was returned, but
no continuum of HIV care data were provided for any stage from 4 countries (Bosnia and Herzegovina, Finland, Iceland, and Turkey).
*In some countries, year of estimate covers .1 year, for example, where the data sources used for different stages relate to different years.
†For Austria, estimates shown are minimum estimates.
FIGURE 1. Overall trends in rates of new HIV diagnoses in the WHO European Region (per 100,000 population) by subregion and
whether HIV continuum data were reportedⱡ in the Dublin Declaration monitoring questionnaire 2016. ⱡThe Dublin Declaration
questionnaire was not returned for Belarus, Former Yugoslav Republic of Macedonia, Liechtenstein, Monaco, Russian Federation,
San Marino, and Turkmenistan, or the questionnaire was returned but no continuum of HIV care data were provided for any stage
for Bosnia and Herzegovina, Finland, Iceland, and Turkey. Surveillance data for the entire period were not available for Bosnia and
Herzegovina and Uzbekistan; thus, these countries are not included in the trends presented above. Data from the ECDC/WHO
HIV/AIDS surveillance in Europe, 2015, was regrouped and analyzed for this graph.
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compared with other subregions (Fig. 1), largely because of
the cases from Russia. In the western subregion, the
situation was reversed with somewhat higher rates of new
diagnoses in the countries reporting continuum data than
those not reporting. Rates were altogether low in the
central subregion.
Of the 44 countries providing continuum data, 37
provided data for stage 1 (number of PLHIV), 42 for stage
2 (number diagnosed), 42 for stage 3 (number on ART), and
31 for stage 4 (number suppressed). Twenty-nine countries
provided data for all 4 stages enabling complete construction
of each of these countries’ continua to be made (Table 2).
Continuum of HIV Care Estimates 2016
An estimated 1,199,107 were PLHIV in the 37 member
states, which provided stage 1 data, equivalent to an overall
HIV prevalence of 0.19%, ranging from 0.02% in Slovakia to
0.84% in Estonia (Table 3). In the 37 countries providing data
for stages 1 and 2, the proportion of PLHIV reported
diagnosed ranged from 38% in Tajikistan to 98% in Romania.
Three countries reported meeting the ﬁrst “90” of the
UNAIDS target.
The proportion on ART among those diagnosed in the
40 countries reporting numbers diagnosed and on ART,
ranged from 27% in Latvia to 96% in Malta and the United
Kingdom. Eight countries reported meeting the second “90”
of the UNAIDS target (Table 2).
Viral suppression rates for the 31 countries providing
data for stages 3 and 4 ranged from 32% in Albania and
Tajikistan to 97% in Switzerland. Eleven countries reported
meeting the third “90” of the UNAIDS target.
The care continua for all 29 countries that provided data
for all stages are shown in Figure 2 (derived from Table 2). In
these countries, the overall continuum of HIV care estimate
corresponding to the UNAIDS target is 81-84-88 (%
diagnosed, % on ART, and % suppressed, respectively),
equating to 60% viral suppression of all PLHIV. These
proportions differed by subregion; 84-88-90, 84-69-62, and
57-45-57 for the western, central, and eastern subregions,
respectively, equivalent to 66%, 36%, and 14% suppressed,
respectively, of all PLHIV. Of note, substantial heterogeneity
in estimates was evident within each subregion.
Two countries in the region reported achieving 90-90-
90 (Sweden and Denmark) equivalent to overall suppression
rates of all PLHIV of 82% and 80%, respectively. The United
Kingdom also reported meeting the overall UNAIDS target of
73% of PLHIV suppressed. Of the remaining countries,
overall suppression rates were $70% for 2 countries, 60%–
69% for 7, 50%–59% for 2, and ,50% for the remaining 15
countries. All 12 countries reporting overall suppression of
$60% are in the western subregion; of the 15 with
suppression rates ,50%, 2 were in the western, 6 in the
central, and 7 in the eastern subregions.
In the 29 countries reporting data for the complete
continuum, 349,329 individuals “lost” from the continuum
TABLE 3. Estimated HIV Prevalence in 37 WHO
European Region Countries Providing Data on Number of









Slovakia 5,420,708 850 0.02%
Hungary 9,854,123 3067 0.03%
Montenegro 622,077 194 0.03%
Serbia 8,850,975 3100 0.04%
Croatia 4,225,002 1680 0.04%
Albania 2,896,679 1400 0.05%
Bulgaria 7,201,840 3543 0.05%
Romania 19,869,088 14,000 0.07%
Austria 8,574,857 6527‡ 0.08%
Sweden 9,745,402 7718 0.08%
Azerbaijan 9,753,968 8798 0.09%
Malta 429,287 394 0.09%
Poland 38,000,496 35,000 0.09%
Denmark 5,658,693 5500 0.10%
Germany 81,180,064 84,700 0.10%
Lithuania 2,920,894 3100 0.11%
Armenia 3,017,712 3600 0.12%
Israel 8,064,036 9720 0.12%
Uzbekistan 29,893,488 36,553 0.12%
Kazakhstan 17,625,226 23,000 0.13%
Greece 10,851,888 14,200 0.13%
Ireland 4,627,985 6180 0.13%
Netherlands 16,898,556 22,900 0.14%




Belgium 11,256,433 17,744 0.16%
Tajikistan 8,481,855 16,000 0.19%
Luxembourg 562,891 1065 0.19%
Switzerland 8,236,123 16,500 0.20%
Italy 60,776,516 127,324 0.21%
France 66,390,704 153,100 0.23%
Georgia 3,999,812 9600 0.24%
Spain 46,434,088 141,000 0.30%
Moldova 4,068,897 17,985 0.44%
Ukraine 44,823,764 223,000 0.50%
Portugal 10,370,756 59,365 0.57%










TOTAL 643,698,640 1,199,107 0.19%
*Eurostat population (denominator) data for 2015 for all age groups.
†Estimates of the number of PLHIV (numerator) provided by country authorities in
the Dublin Declaration questionnaire 2016 for the most recent year of data available (no
restriction by age).
‡Estimate for PLHIV generated using Austrian cohort data, which covers approx.
76% of PLHIV in Austria.
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FIGURE 2. The HIV continuum of care in the WHO European Region for 29 countries submitting data for all 4 stages in the Dublin
Declaration monitoring questionnaire 2016. ART antiretroviral treatment proportions are shown out of the previous stage, ie, %
diagnosed out of the number of PLHIV, % on ART of those diagnosed, and % virally suppressed of those on ART.
FIGURE 3. Relative contributions to the overall pool of unsuppressed viremia by stage of the HIV continuum of care in 29
countries in the WHO European Region reporting all 4 stages in the Dublin Declaration monitoring questionnaire 2016. Figures in
bars are estimated numbers of individuals with unsuppressed viremia at each stage. Data are cross-sectional and do not reflect the
time spent at each stage.
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comprised the total pool of people living with unsuppressed
viremia. The relative contributions of each stage to the overall
total unsuppressed were: an estimated 165,322 (47%) with
undiagnosed HIV, 110,657 (32%) diagnosed who are not on
ART, and 73,350 (21%) on ART without suppressed virus.
These proportions equate to 48%, 30%, and 22% for
undiagnosed, diagnosed not on ART, and on ART unsup-
pressed, respectively, in the western subregion, 25%, 40%,
and 34% for the central subregion, and 51%, 36%, and 13%
for the eastern subregion (Fig. 3).
Progress Since 2014
Submission of continuum of HIV care data improved
from 2014 to 2016: more countries provided estimates for at
least 1 stage (44 in 2016 vs. 40 in 2014) and more submitted
data for all 4 stages (29 vs. 16).
The estimated care continuum in 2016 was somewhat
improved for the 16 countries reporting complete data in both
2014 and 2016 from 76-80-88 to 83-89-90. In 2016, a greater
number of countries reported reaching $90% on ART (8/40
vs. 2/33 in 2014) and $90% suppressed (11/31 vs. 9/24);
the same number reported reaching $90% diagnosed (3/37
vs. 3/23).
Of the 48 countries, which provided information on
CD4 threshold for ART initiation in 2014, 4 countries
recommended initiation regardless of CD4 cell count. By
2016, of the 48 countries providing this information, this
ﬁgure reached 29.
Challenges With Collecting and Reporting
Continuum Data
Thirty countries responded to a question about the main
challenges in collecting continuum data and/or gave reasons
for not providing continuum of care estimates. Key chal-
lenges can be summarized as follows, in no particular order:
• Lack of a consolidated national clinical data source,
regularly updated, for example, through a cohort, from
which numbers on ART and suppressed can be derived;
• Lack of a single source from which data to estimate all
stages could be collated;
• Where clinical cohort data exist, the lack of a common
identiﬁer to allow for linkage with surveillance data;
• Inadequate data systems, for example, lack of/low quality
of case reporting, or lack of electronic data;
• Lack of data and/or expertise to estimate number
of PLHIV;
• Lack of ﬁnancial and human resources to collect and
analyze data.
DISCUSSION
Using data reported by countries through the Dublin
Declaration questionnaire in 2016, we estimate the continuum
of HIV care to be 81-84-88 for the WHO European Region,
based on the 29 countries with complete continuum data. This
equates to 60% of all PLHIV being suppressed. Although
these ﬁgures represent an improvement over the 2014
estimates,14,15 a concerted effort is clearly needed if the
region is to reach the 90-90-90 target by 2020 given the high
proportion unsuppressed.
Two countries in the region have, to date, achieved the
UNAIDS target: Sweden and Denmark. Although this
achievement is to be applauded, it is worth bearing in mind
that estimated HIV prevalence in these countries is among the
lowest in the western subregion. Their greater achievement
may, therefore, be successful HIV-prevention interventions.
We also noted wide heterogeneity in estimates across
the region, and within subregions. The care continuum is
highest in the western subregion, and lowest in the eastern
subregion. With an estimated care continuum of 84-88-90,
many countries in the western subregion are much closer to
reaching the 73% overall viral suppression target by 2020. At
57-45-57, a number of countries in the eastern subregion are
lagging behind, possibly reﬂecting the younger epidemics in
some. At current rates, they face major challenges in meeting
the UNAIDS target. Given the substantial heterogeneity in
estimates for each stage within each subregion, the focus
should be on each country’s continuum rather than that of the
subregion within which it is located.
The continuum estimates presented here are comparable
with, although somewhat higher than, ﬁndings from recent
systematic analyses of published care continua for countries
worldwide, including WHO European Region countries.16,17
Although there may be differences between countries in
methodologies and populations on which estimations are
based, the data may be an indication of genuine improvements,
given that these are largely the most recent estimates. Our
estimates here are also comparable with recent estimates from
UNAIDS4 and for 11 European Union countries in 2013.18
We found that countries in the eastern subregion that
did not provide any continuum data, for example, Russia and
Belarus, had higher rates of new HIV diagnoses, more than
double those reporting continuum data. Given that the rate in
the eastern subregion is dominated by Russia, one of the 11
countries not submitting data through the Dublin Declaration
questionnaire, our overall estimates for the region, as a whole,
and in Eastern Europe, in particular, are almost certainly over-
optimistic.
There was no single stage for which data were
available for all countries. The ﬁrst stage, total estimated
number of PLHIV, is arguably the most crucial as all
subsequent stages depend on it and presents the greatest
challenge to derive. An accurate estimate of this stage is,
nonetheless, essential for planning, budgeting, implement-
ing, and monitoring the national response to HIV. In the
European region, only 37 countries provided these esti-
mates in 2016, and greater effort is, therefore, required to
support countries, particularly where no historical surveil-
lance data are available. To help address this, the ECDC is
supporting countries to use the ECDC HIV modeling tool
to generate robust estimates of the number of PLHIV.19
Data for 12 countries with PLHIV estimates in a recent
WHO publication were similar to our ﬁndings,20 with the
exception of 3 countries for which estimates differed by
$10% (Azerbaijan, Uzbekistan, and Greece).
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Furthermore, the number undiagnosed is responsible for
the largest share of unsuppressed viremia because of the
number of individuals involved. We estimated that, across the
whole region, it accounts for 47% of the total unsuppressed.
Even in the western subregion, with 84% of all estimated
PLHIV diagnosed, those remaining undiagnosed account for
48% of the total unsuppressed. These calculations highlight
the importance of testing and diagnosis, given the potential
for onward transmission from the large numbers undiagnosed.
Although the length of time spent by individuals in each stage
is not taken into account, these calculations likely underes-
timate the potential contribution to transmission of undiag-
nosed populations, given that some may remain in that stage
for many years.
Changes to ART initiation guidelines are likely to have
inﬂuenced the apparent improvement in the proportions on
ART between 2014 and 2016 (from 80% to 89%). After the
results of the START21 and TEMPRANO22 trials of when to
initiate ART, most HIV treatment guidelines now recommend
ART initiation on diagnosis, without the need of a CD4+ cell
count.23 This change is, indeed, reﬂected in the data collected
through the Dublin Declaration questionnaire, with 41 of the
48 countries reporting policies of initiating ART at CD4+ 500
cells/mm3 or higher. No doubt changes will follow for the
remaining countries still using lower CD4+ thresholds.
Beyond lack of access to ART, those who are diagnosed
but not linked to or retained in care are also likely to account
for the loss in numbers from the continuum at this stage.
Viral suppression rates are not expected to be 100% in
any country, given that this ﬁgure will always include
individuals who, at any 1 time, are newly diagnosed and/or
have recently initiated ART and not yet reached viral
suppression. However, this stage accounts for an appreciable
proportion of potential HIV transmission, and the use of drugs
in ART regimens that lead to rapid reductions in viremia after
ART initiation is the key to reducing the risk of HIV
transmission from treated individuals.
Limitations
The major limitation to our ﬁndings is that there is no
centralized quality assurance mechanism for all countries in
the region, and limited information was provided by countries
on how exactly these estimates were derived. For example,
for stages 2, 3, and 4, countries responded on whether cohort
or surveillance, or another source of data, was used, but not
speciﬁcally on how the estimates were derived. Rather, we
were reliant on accurate and robust data being provided by the
appropriate authority in each country. Although standardized
deﬁnitions for each stage of the care continuum were
provided, it is unlikely that they were strictly applied by
every country, often reﬂecting constraints on available data
sources. Differences between countries may, therefore, be due
to differences in methodology. Nonetheless, we take this
opportunity to reiterate the call given by others14,16,17,24,25
and ourselves previously18,26 that countries should use at least
broadly similar deﬁnitions.
The lack of a single source from which all stages of the
continuum can be estimated or an identiﬁer that allows for
linkage across different sources of data was cited by many as
a major challenge. Although the availability of national
cohorts is a valuable resource, innovative solutions are called
for where these do not exist, such as the creation of virtual
national cohorts through regular contact between government
agencies and the centers providing HIV care. Investment,
training, and support to countries are also needed to overcome
any limitations in ﬁnancial and technical capacity for collect-
ing and analyzing care continuum data.
The analyses reported here, together with policy outputs
associated with the Dublin Declaration monitoring process,27
highlight the need for intensiﬁed efforts if the region is to
achieve the 90-90-90 target. It is worth bearing in mind;
however, that reaching this target is not the overarching goal,
which is to eliminate new infections and deaths. Nonetheless,
the target serves as a yardstick by which governments and
program directors can measure the success of their HIV care
programs and be alerted to key areas that need
speciﬁc attention.
CONCLUSIONS
Based on the evidence, we conclude with a number of
recommendations that will help the region to achieve and
surpass the 90-90-90 target. First, HIV testing programs
need to be strengthened in all subregions, but especially in
Eastern Europe. Crucial to the effective implementation of
any testing program is the production of the subnational
estimates of the undiagnosed epidemic28 and the removal
of barriers to testing. Second, to increase their uptake,
national HIV testing policies need to incorporate innova-
tive approaches to testing, including community-based
testing, self-testing, and home sampling. Third, there is
an urgent need to reduce missed opportunities for HIV
diagnosis in health services, particularly in primary care,
through the adoption of routine or opt-out testing, where
appropriate, and by implementing indicator condition-
guided testing. Fourth, because early initiation of ART
has been shown to be efﬁcacious in improving the health
outcomes of PLHIV and in reducing their viral load that, in
turn, reduces the risk of transmitting HIV to others, a “test
and treat” policy needs to be implemented in all countries
in line with international guidelines. Fifth, access to
treatment needs to be available to all, and barriers to such
access need to be identiﬁed and removed, referral mech-
anisms strengthened, and laws that discriminate against key
populations eliminated. Finally, close attention to the
quality of HIV treatment and care provided is needed, to
maximize the chance that all patients achieve sustained
viral suppression, including the use of routine laboratory
monitoring and adherence support.
In conclusion, there are wide disparities in the HIV
continuum of care in the WHO European Region.
Although countries in the western subregion are generally
closing in on reaching 90-90-90, many countries in the
central and eastern subregions are lagging far behind. It is
difﬁcult to envisage that a country can achieve 90-90-90 if
it is unable to produce an accurate estimate of this
measure. Priority needs to be given to resources which
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allow countries to address the challenge of producing
robust continuum estimates and tracking progress toward
achieving that goal.
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APPENDIX 1. Members of the ECDC Dublin
Declaration Monitoring Network
Members of the ECDC Dublin Declaration monitoring network
include: Roland Bani (Albania), Montse Gessé (Andorra), Samvel Gri-
goryan (Armenia), Irene Rueckerl, Bernhard Benka, Robert Zangerle
(Austria), Esmira Almammadova (Azerbaijan), Daniel Reynders, Andre
Sasse, Dominique Van Beckhoven (Belgium), Šerifa Godinjak, Drazenka
Malicbegovic, Indira Hodzic (Bosnia and Herzegovina), Tonka Varleva
(Bulgaria), Jasmina Pavlic, Tatjana Nemeth-Blazic (Croatia), Linos Hadji-
hannas, Anna Demetriou (Cyprus), Veronika Šikolová, Hana Janatova
(Czech Republic), Jan Fouchard, Susan Cowan (Denmark), Kristi Rüütel,
Anna-Liisa Pääsukene (Estonia), Henrikki Brummer-Korvenkontio
(Finland), Jean-Christophe Comboroure. Florence Lot (France), Maia
Tsereteli, Ana Aslanikashvili (Georgia), Gesa Kupfer, Ulrich Marcus,
(Germany), Vasileia Konte (Greece), Katalin Szalay, Krisztina Tálas
(Hungary), Guðrún Sigmundsdóttir (Iceland), Caroline Hurley, Fiona
Lyons (Ireland), Daniel Chemtob, Rivka Rich (Israel), Francesco Maragli-
no, Anna Caraglia, Barbara Suligoi, Lella Cosmaro (Italy), Irina Ivanova
Petrenko, Alla Yelizarieva, Aliya Bokazhanova (Kazakhstan), Laura
Shehu, Pashk Buzhala [Kosovo (This designation is without prejudice to
positions on status, and is in line with UNSC 1244 and the ICJ Opinion on
the Kosovo Declaration of Independence.)], Aikul Ismailova, Nazgul
Asybaliev, Talgat Mambetov, Saliya Karymbaeva, Umutkan Chokmorova,
Lucia Yanbuhtina, (Kyrgyzstan), Šarlote Konova (Latvia), Irma Caplin-
skiene (Lithuania), Patrick Hoffman, Pierre Weicherding (Luxembourg),
Jackie Maistre Melillo, Charmaine Gauci (Malta), Violeta Teutu, Tatiana
Cotelnic-Harea (Moldova), Maja Milanović, Aleksandra Marjanovic, Alma
Cicic (Montenegro), Silke David, Eline Op De Coul (Netherlands), Arild
Johan Myrberg (Norway), Iwona Wawer, Piotr Wysocki, Adam Adamus,
Wojciech Tomczynski (Poland), Antonio Diniz, Isabel Aldir, Teresa Melo
(Portugal), Mariana Mardarescu (Romania), Danijela Simic, Sladjana Baros
(Serbia), Peter Truska (Slovakia), Irena Klavs (Slovenia), Olivia Castillo,
Begoña Rodríguez Ortiz de Salazar, Asuncion Diaz (Spain), Maria
Axelsson, Louise Mannheimer, Kristina Ingemarsdotter Persson (Sweden),
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Stefan Enggist, Axel J. Schmidt (Switzerland), Alijon Soliev, Sayfuddin
Karimov, Dilshod Sayburhonov (Tajikistan), Emel Özdemir S¸ahin
(Turkey), Valerie Delpech, Peter Kirwan, Alison Brown, Sara Croxford,
Sandra Okala (United Kingdom), Igor Kuzin, Olga Varetskaya (Ukraine),
and Zulﬁya Abdurakhimova, Nurmat Atabekov (Uzbekistan).
APPENDIX 2.
Questionnaires were sent to the Competent Bodies of the ECDC,
their respective director’s ofﬁce and their nominated experts in each
country. In some instances, it is the Ministries of Health that are responsible
for reporting directly to the ECDC. Austria: Federal Ministry of Health,
Belgium: Sciensano, Bulgaria: National Centre of Infectious and Parasitic
Diseases, Croatia: Croatian National Institute of Public Health, Cyprus:
Director of Medical and Public Health Services, Czech Republic: National
Institute of Public Health, Denmark: Danish Health and Medicines
Authority, Estonia: Health Board, Finland: National Institute for Health
and Welfare, France: French Public Health Agency, Germany: Robert Koch
Institute, Greece: Hellenic Centre for Disease Control and Prevention,
Hungary: Deputy State Secretariat for Chief Medical Ofﬁcer’s Affairs of
the Ministry of Human Capacities, Iceland: Centre for Health Security and
Communicable Disease Control Directorate of Health, Ireland: Health
Protection Surveillance Centre, Italy: Ministry of Health, Latvia: Centre for
Disease Prevention and Control, Liechtenstein: Principality of Liechten-
stein, Lithuania: Health Directorate, Malta: Superintendence of Public
Health, Netherlands: National Institute for Public Health and Environment,
Norway: Norwegian Institute of Public Health, Poland: National Institute of
Public Health/National Institute of Hygiene, Portugal: Directorate General
of Health, Romania: National Institute of Public Health, Slovakia: Public
Health Authority of the Slovak Republic, Slovenia: National Institute of
Public Health, Spain: Ministry of Health, Social Services and Equality,
Sweden: Public Health Agency of Sweden, and United Kingdom: Public
Health England. For countries outside the EU/EEA, the ECDC does not
have Competent Bodies, in which case, the questionnaire was sent to the
Ministry of Health contact points, national AIDS coordinators, or
nominated national surveillance experts at public health institutes.
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